Thermo Fisher Scientific and the Biopharmaceutical Analysis Training Laboratory (BATL) at Northeastern University, have entered into a collaborative agreement to advance analytical capabilities and drive innovation across the biopharmaceutical industry in areas including personalized medicine, monoclonal antibodies and gene and cell therapies.

BATL’s technical training programs for regulators, industry personnel and academics, leveraging Thermo Fisher’s ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) technology, aims to facilitate the development of cutting-edge analytical solutions and delivery of training designed to meet current industry needs.

The implementation of the Thermo Scientific Orbitrap Exploris 240 mass spectrometer and Thermo Scientific Vanquish Duo UHPLC System within BATL’s training facility will offer the accuracy, precision and reliability required to analyze the complex molecules. Utilizing the power of these analytical systems, researchers at BATL will be in a position to develop robust chromatography-based workflows for the streamlined analysis of biotherapeutics and share these methods across the industry to drive analytical advancements.

BATL has implemented the Orbitrap Exploris 240 mass spectrometer to meet the requirements of late-stage biopharmaceutical developers for application flexibility, improved accuracy, and rapid turnaround times. The Orbitrap Exploris 240 mass spectrometer typically works across an extensive range of samples of varying characteristics. BATL also selected the Vanquish Duo UHPLC System for its ability to be operated in tandem mode, eliminating wait time for column equilibration, thereby further accelerating biopharmaceutical analyses.